BG98523A - Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b - Google Patents

Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b

Info

Publication number
BG98523A
BG98523A BG98523A BG9852394A BG98523A BG 98523 A BG98523 A BG 98523A BG 98523 A BG98523 A BG 98523A BG 9852394 A BG9852394 A BG 9852394A BG 98523 A BG98523 A BG 98523A
Authority
BG
Bulgaria
Prior art keywords
virus
hepatite
ctl
hla
lymphocytic
Prior art date
Application number
BG98523A
Other languages
Bulgarian (bg)
English (en)
Inventor
Maria Vitiello
Robert Chesnut
Original Assignee
Cytel Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytel Corporation filed Critical Cytel Corporation
Publication of BG98523A publication Critical patent/BG98523A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BG98523A 1991-08-26 1994-02-22 Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b BG98523A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74956891A 1991-08-26 1991-08-26
US82768292A 1992-01-29 1992-01-29
US87449192A 1992-04-27 1992-04-27
PCT/US1992/007218 WO1993003764A1 (en) 1991-08-26 1992-08-26 Hla-restricted hepatitis b virus ctl epitopes

Publications (1)

Publication Number Publication Date
BG98523A true BG98523A (en) 1995-05-31

Family

ID=27419385

Family Applications (1)

Application Number Title Priority Date Filing Date
BG98523A BG98523A (en) 1991-08-26 1994-02-22 Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b

Country Status (16)

Country Link
EP (2) EP0534615B1 (sv)
JP (2) JP3738395B2 (sv)
AU (1) AU687725B2 (sv)
BG (1) BG98523A (sv)
CA (1) CA2115839C (sv)
CZ (1) CZ42794A3 (sv)
DE (1) DE69231621T2 (sv)
ES (1) ES2155060T3 (sv)
FI (1) FI940918A (sv)
GR (1) GR3035575T3 (sv)
HU (1) HUT68510A (sv)
IL (1) IL102964A0 (sv)
NO (1) NO940660L (sv)
NZ (2) NZ244103A (sv)
OA (1) OA09888A (sv)
WO (1) WO1993003764A1 (sv)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US6322789B1 (en) 1991-08-26 2001-11-27 Epimmune, Inc. HLA-restricted hepatitis B virus CTL epitopes
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US6689363B1 (en) 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
EP1704868A1 (en) * 1992-08-07 2006-09-27 Pharmexa Inc. HLA binding peptides and their uses
US6235288B1 (en) 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
DK0708656T3 (da) * 1993-04-27 2002-12-02 United Biomedical Inc Antigene LHRH peptidkonstruktioner og universelle syntetiske immunstimulatorer til vacciner
ATE415173T1 (de) 1993-09-14 2008-12-15 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
GB9325772D0 (en) * 1993-12-16 1994-02-16 Smithkline Beecham Biolog Novel compounds
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
JP2001508054A (ja) * 1996-12-30 2001-06-19 イノジェネティックス・ナムローゼ・フェンノートシャップ ＨＢｓＡｇ由来アネキシンＶ結合ポリペプチドおよびその使用
NZ500287A (en) * 1997-04-11 2002-10-25 Sangstat Medical Corp Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
US20010019714A1 (en) * 1998-04-07 2001-09-06 Charles D. Y. Sia Hiv-specific cytotoxic t-cell responses
US7105164B1 (en) 1998-04-07 2006-09-12 Sanofi Pasteur Limited HIV-specific cytotoxic T-cell responses
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
EP2177534A3 (en) 1999-11-18 2010-07-14 Pharmexa Inc. Heteroclitic analogs of class i epitopes
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
WO2005108416A2 (en) * 2004-04-21 2005-11-17 The University Of Chicago Myosin light chain kinase inhibitors and their use
CA2660830A1 (en) * 2006-08-14 2008-02-21 Gideon Goldstein Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of hiv-1
CN102850435B (zh) 2006-10-17 2016-02-17 肿瘤疗法科学股份有限公司 用于表达mphosph1或depdc1多肽的癌症的肽疫苗
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
RU2530555C2 (ru) 2008-04-17 2014-10-10 ПиДиЭс БАЙОТЕКНОЛОДЖИ КОРПОРЭЙШН Стимуляция иммунного ответа энантиомерами катионных липидов
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
CN102573903B (zh) 2009-08-07 2015-12-02 特兰斯吉恩股份有限公司 用于治疗hbv感染的组合物
US10076570B2 (en) 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Ｈｂｖ聚合酶突變體
US9458447B2 (en) 2011-08-12 2016-10-04 Oncotherapy Science, Inc. MPHOSPH1 peptides and vaccines including the same
WO2013036201A1 (en) * 2011-09-06 2013-03-14 Agency For Science, Technology And Research Polypeptide vaccine
CN105101991A (zh) 2012-09-21 2015-11-25 Pds生物科技公司 改进的疫苗组合物和使用方法
CA2840937A1 (en) * 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for transdermal administration
US20140234377A1 (en) * 2013-02-05 2014-08-21 Nitto Denko Corporation Vaccine composition for mucosal administration
IL257335B (en) 2015-08-12 2022-08-01 Oncotherapy Science Inc A depdc1-derived peptide and a component containing it
US10835600B2 (en) * 2015-09-08 2020-11-17 Universität Zürich Compositions against cat allergy
JP6857909B2 (ja) 2015-10-08 2021-04-14 オンコセラピー・サイエンス株式会社 Ｍｐｈｏｓｐｈ１由来ペプチドおよびそれを含むワクチン
CA3005251A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935235A (en) * 1979-05-24 1990-06-19 The Regents Of The University Of California Non-passageable viruses
US5017558A (en) * 1980-01-14 1991-05-21 The Regents Of The University Of California Synthetic vaccine peptide epitomes of hepatitis B surface antigen
JPS60161999A (ja) * 1984-02-02 1985-08-23 Chemo Sero Therapeut Res Inst ペプチド
US4818527A (en) * 1986-12-09 1989-04-04 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
EP0420913B1 (en) * 1988-06-14 1995-11-15 Cell Med, Inc. Heterofunctional cellular immunological reagents, vaccines containing same and methods for the use of same
IT1238343B (it) * 1989-10-16 1993-07-13 Cesalpino Andrea Fond Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche
US5480967A (en) * 1990-01-05 1996-01-02 United Biomedical, Inc. HIV-1 core protein fragments

Also Published As

Publication number Publication date
NZ270605A (en) 1997-07-27
CA2115839C (en) 2010-06-01
DE69231621D1 (de) 2001-02-08
JP3738395B2 (ja) 2006-01-25
EP1018344A3 (en) 2000-09-20
HU9400581D0 (en) 1994-05-30
EP1018344A2 (en) 2000-07-12
EP0534615A2 (en) 1993-03-31
AU2548792A (en) 1993-03-16
NO940660L (no) 1994-04-22
JP3586278B2 (ja) 2004-11-10
WO1993003764A1 (en) 1993-03-04
JP2004075693A (ja) 2004-03-11
NO940660D0 (no) 1994-02-25
FI940918A (sv) 1994-04-08
IL102964A0 (en) 1993-01-31
FI940918A0 (sv) 1994-02-25
CA2115839A1 (en) 1993-03-04
ES2155060T3 (es) 2001-05-01
OA09888A (en) 1994-09-15
HUT68510A (en) 1995-06-28
NZ244103A (en) 1997-07-27
CZ42794A3 (en) 1994-11-16
JPH06510051A (ja) 1994-11-10
GR3035575T3 (en) 2001-06-29
EP0534615B1 (en) 2001-01-03
EP0534615A3 (en) 1994-05-25
DE69231621T2 (de) 2001-05-31
AU687725B2 (en) 1998-03-05

Similar Documents

Publication Publication Date Title
BG98523A (en) Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b
PT1294893E (pt) Modificacao do antigenio nuclear de hepatite b
RU94042722A (ru) Химерный белок, ген, клетка, вектор, способ получения химерного белка, вакцина
DK0610250T3 (da) Vaccine med porcint reproduktivt respiratorisk syndrom og diagnose heraf
YU48250B (sh) Postupak za pripremanje aktivne vakcine protiv lajmske bolesti
DK0528859T3 (da) Oral vaccine, som omfatter antigen knyttet til overfladen af røde blodlegemer
ATE402715T1 (de) Hcv-impfstoff zusammensetzungen
WO2006041866A3 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
DE69327587T2 (de) Konjugate von schwach immunogenen antigenen und synthetischen peptidträgern und impfstoffe diese enthaltend
ATE97815T1 (de) Kombiniertes hepatitis a- und b-vakzin mit adjuvans.
NO940661L (no) Peptider for indusering av cytotoksisk T-lymfocytreaksjoner mot hepatit B virus
EA200300129A1 (ru) Очистка антигенов вируса гепатита b (hbv) для применения в вакцинах
Dezfuli et al. Induction of IFN-γ cytokine response against hepatitis B surface antigen using melittin
Deresinski Concurrent Plasmodium vivax malaria and dengue
EP0881910A4 (en) USE OF IMMUNOCONJUGATES TO ENHANCE THE EFFICACY OF MULTI-STEP VACCINES STIMULATING IMMUNE REACTIONS IN CASCADE
SE9202968D0 (sv) New peptides, diagnostic antigens, use thereof, vaccines and medicaments
WO2002057314A3 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational epitopes
WO2004005316A3 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
WO2017084518A1 (zh) 一种疫苗佐剂以及包含该佐剂的疫苗
NZ295056A (en) Hepatitis virus e strain, recombinant proteins thereof, use in diagnostic methods and vaccines
ATE185073T1 (de) Impfstoff zubereitungen
Karl et al. Antibodies produced by rabbits immunized with visna virus
Pütz et al. The rationale of a peptide-conjugate vaccine against measles
ATE409705T1 (de) Pre-s-protein von hepatitis-b-virus (hbv) als adjuvans und komponente eines hbv-impfstoffs
McLaren et al. Immunity to influenza in ferrets: XII. Immunization of ferrets with TNBP-split influenza virus vaccine